OKYO Pharma plans 111-patient global eye pain trial

The planned global Phase 3 urcosimod trial is intended to evaluate a single-dose regimen in approximately 111 patients with neuropathic corneal pain.

Rhea-AI Filing Summary

OKYO Pharma Ltd (OKYO) announced it will present and participate at ophthalmic conferences. The American Academy of Optometry takes place September 30 to October 1, 2026, in Anaheim, where the company’s leadership team will engage optometric experts; the American Academy of Ophthalmology is scheduled for October 9–12, 2026, in New Orleans, for engagement with ophthalmology experts. At Eyecelerator in New Orleans on October 8, Chief Executive Officer Robert J. Dempsey is scheduled to present “Addressing Unmet Needs in Corneal and Anterior Segment Diseases” at 1:29 p.m. in the Anterior Segment breakout, Room 243–245.

OKYO also said it plans to initiate a global Phase 3 pivotal clinical trial of urcosimod in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen for neuropathic corneal pain. The release describes the company as developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

Key Figures

Planned trial enrollment: Approximately 111 patients Planned trial timing: Second half of this year Eyecelerator presentation date: October 8, 2026 +3 more

6 metrics

Planned trial enrollment Approximately 111 patients Global Phase 3 pivotal clinical trial of urcosimod

Planned trial timing Second half of this year Planned initiation of the global Phase 3 pivotal clinical trial

Eyecelerator presentation date October 8, 2026 New Orleans

Presentation time 1:29 p.m. Eyecelerator

American Academy of Optometry dates September 30 to October 1, 2026 Anaheim

American Academy of Ophthalmology dates October 9–12, 2026 New Orleans

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, urcosimod, Phase 3 pivotal clinical trial, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

urcosimod medical

"single-dose regimen of urcosimod"

Phase 3 pivotal clinical trial medical

"initiate a global Phase 3 pivotal clinical trial"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"evaluate a single-dose regimen of urcosimod"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will OKYO present at Eyecelerator?

Chief Executive Officer Robert J. Dempsey is scheduled to present “Addressing Unmet Needs in Corneal and Anterior Segment Diseases” on October 8, 2026, at 1:29 p.m. in the Anterior Segment breakout, Room 243–245, in New Orleans.

What clinical trial is OKYO planning for urcosimod?

OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen for neuropathic corneal pain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 07:00 AM Accepted by SEC EDGAR 09/29/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 29, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that it will present and participate at upcoming ophthalmic conferences.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: September 29, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated September 29, 2026

4

Exhibit 99.1

 

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

● OKYO demonstrates continued commitment to optometry and ophthalmology

London and New York, NY, September 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026

New Orleans, Louisiana

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases

Presentation Date/Time: Thursday, October 8, 2026, 1:29PM CT

Breakout: Anterior Segment, Room 243-245

Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma

Moderators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD

American Academy of Optometry takes place September 30 - October 1 in Anaheim where the leadership team will engage leading optometric experts.

American Academy of Ophthalmology takes place October 9-12 in New Orleans where the leadership team will engage with leading ophthalmology experts.

The Company’s continued presence at leading ophthalmic meetings supports its commitment to engaging both optometrists and ophthalmologists, who both play a role in the diagnosis and care of patients with neuropathic corneal pain (NCP).

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 11.5 KB
• EX-99 GRAPHIC 31.9 KB